
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
Recommendations for using AR-targeted therapy as an approach when managing patients with metastatic castrate-sensitive prostate cancer.
Case: A 66-Year-Old Male with Metastatic Castrate-Sensitive Prostate Cancer
Initial presentation
Clinical Workup
Treatment and Follow-Up
